CP 870893

Drug Profile

CP 870893

Alternative Names: CP-870,893

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA); Pfizer; Sir Charles Gairdner Hospital
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; CD40 antigen inhibitors; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant melanoma
  • Discontinued Mesothelioma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Adjuvant therapy) in USA (IV, Infusion)
  • 31 Aug 2012 CP 870893 licensed to VLST Corporation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top